Journey Medical (DERM) to Release Quarterly Earnings on Monday

Journey Medical (NASDAQ:DERM) is scheduled to issue its quarterly earnings data after the market closes on Monday, May 13th. Analysts expect the company to announce earnings of ($0.26) per share for the quarter.

Journey Medical (NASDAQ:DERM) last issued its quarterly earnings data on Thursday, March 21st. The company reported ($0.12) earnings per share for the quarter. Journey Medical had a negative net margin of 4.87% and a negative return on equity of 34.08%. The company had revenue of $15.26 million during the quarter, compared to the consensus estimate of $15.80 million. On average, analysts expect Journey Medical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Journey Medical Stock Up 1.2 %

NASDAQ:DERM opened at $3.48 on Wednesday. The company has a market capitalization of $69.36 million, a price-to-earnings ratio of -9.83 and a beta of 0.78. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.10 and a current ratio of 1.35. Journey Medical has a 12 month low of $1.02 and a 12 month high of $8.11. The company has a 50 day moving average price of $3.67.

Insider Buying and Selling at Journey Medical

In related news, CEO Claude Maraoui acquired 10,000 shares of the business’s stock in a transaction dated Friday, March 22nd. The stock was acquired at an average price of $3.48 per share, with a total value of $34,800.00. Following the completion of the transaction, the chief executive officer now owns 2,163,430 shares of the company’s stock, valued at $7,528,736.40. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Claude Maraoui acquired 10,000 shares of the stock in a transaction dated Friday, March 22nd. The shares were acquired at an average cost of $3.48 per share, for a total transaction of $34,800.00. Following the completion of the transaction, the chief executive officer now owns 2,163,430 shares in the company, valued at approximately $7,528,736.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Justin Adam Smith acquired 30,000 shares of the company’s stock in a transaction dated Friday, March 22nd. The stock was acquired at an average price of $3.47 per share, with a total value of $104,100.00. Following the purchase, the director now owns 134,717 shares in the company, valued at approximately $467,467.99. The disclosure for this purchase can be found here. Insiders purchased a total of 50,000 shares of company stock valued at $169,300 in the last ninety days. Company insiders own 19.42% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Alliance Global Partners began coverage on Journey Medical in a research report on Friday, February 16th. They set a “buy” rating and a $8.50 price objective for the company.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.